Clinical Biomarkers of Dyslipidemia in Diabetes Mellitus Type II Patients

  • Ali Afzal University of Chinese Academy of Sciences, Shenzhen, Chinese Mainland; University of Central Punjab, Lahore, Pakistan.
  • Robina Kausar University of Narowal, Narowal, Pakistan
  • Sana Aslam University of Narowal, Narowal, Pakistan
  • Nayab Shahid University of Central Punjab, Lahore, Pakistan
  • Suneela Aman University of Veterinary and Animal Sciences, Lahore, Pakistan
  • Muhammad Zohaib Government College University, Lahore, Pakistan
  • Amna Rehman University of the Punjab, Lahore, Pakistan
  • Nimra Afzal University of Central Punjab, Lahore, Pakistan
  • Mudassir Hassan Abbasi University of Okara, Pakistan
  • Nadeem Sheikh University of the Punjab, Lahore, Pakistan
  • Muhammad Babar Khawar University of Narowal, Narowal, Pakistan; Yangzhou University, Yangzhou, Chinese Mainland‎
Keywords: biomarkers, cholesterol, dyslipidemia, lipids, type II diabetes mellitus (TBDM)

Abstract

Abstract Views: 708

Background. This study aims to comparatively investigate the clinical biomarkers of diabetic dyslipidemia in type II diabetes mellitus (TIIDM) patients and healthy controls with no clinical diabetic history.

Method. A cross-sectional study was conducted on 100 TIIDM patients age-matched with 100 control subjects. They were evaluated from January 2021 to July 2022 in Narowal, Pakistan. Various biomarkers including total cholesterol (TL), low-density lipoprotein (LDL), high-density lipoprotein (HDL), and triglycerides were measured for each subject.

Results. The results showed significantly higher levels of TC (238 ± 30 mg/dl), triglycerides (201 ± 72 mg/dl), and LDL (141 ± 47 mg/dl) in TIIDM patients as compared to control groups’ levels of TC (167 ± 23 mg/dl), triglycerides (175 ± 75 mg/dl), and LDL (95 ± 30 mg/dl). However, HDL level was significantly lower (46 ± 21 mg/dl) in TIIDM patients as compared to control group (54 ± 27 mg/dl).

Conclusion. The clinical biomarkers of dyslipidemia are effective risk predictors for cardiovascular diseases in low-income countries such as Pakistan.

 

Downloads

Download data is not yet available.

Author Biographies

Ali Afzal , University of Chinese Academy of Sciences, Shenzhen, Chinese Mainland; University of Central Punjab, Lahore, Pakistan.

 

 

 

 

Robina Kausar, University of Narowal, Narowal, Pakistan

 

 

 

Nayab Shahid, University of Central Punjab, Lahore, Pakistan

 

 

Suneela Aman, University of Veterinary and Animal Sciences, Lahore, Pakistan

 

 

Nimra Afzal, University of Central Punjab, Lahore, Pakistan

 

 

 

References

Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas. Diabetes Res Clin Pract. 2019;157:e107843. https://doi.org/10.1016/j.diabres.2019.107843 DOI: https://doi.org/10.1016/j.diabres.2019.107843

Basit A, Fawwad A, Qureshi H, Shera AS. Prevalence of diabetes, pre-diabetes and associated risk factors: second National Diabetes Survey of Pakistan (NDSP), 2016–2017. BMJ Open. 2018;8(8):e020961. https://doi.org/10.1136/bmjopen-2017-020961 DOI: https://doi.org/10.1136/bmjopen-2017-020961

Astrup A, Finer N. Redefining type 2 diabetes:‘diabesity’or ‘obesity dependent diabetes mellitus’? Obes Rev. 2000;1(2):57–59. https://doi.org/10.1046/j.1467-789x.2000.00013.x DOI: https://doi.org/10.1046/j.1467-789x.2000.00013.x

Krauss RM. Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care. 2004;27(6):1496–1504. https://doi.org/10.2337/diacare.27.6.1496 DOI: https://doi.org/10.2337/diacare.27.6.1496

Fletcher B, Gulanick M, Lamendola C. Risk factors for type 2 diabetes mellitus. J Cardiovas Nurs. 2002;16(2):17–23. DOI: https://doi.org/10.1097/00005082-200201000-00003

Midhet FM, Al-Mohaimeed AA, Sharaf FK. Lifestyle related risk factors of type 2 diabetes mellitus in Saudi Arabia. Saudi Med J. 2010;31(7):768–774.

Al-Shammari FKH, Al-Meraghi O, Nasif A, Al-Otaibi S. The prevalence of diabetic retinopathy and associated risk factors in type 2 diabetes mellitus in Al-Naeem area (Kuwait). Middle East J Fam Med. 2005;3(2):e3.

Ding H, Triggle CR. Endothelial cell dysfunction and the vascular complications associated with type 2 diabetes: assessing the health of the endothelium. Vasc Health Risk Manag. 2005;1(1):55–71. https://doi.org/10.2147/vhrm.s115558939 DOI: https://doi.org/10.2147/vhrm.1.1.55.58939

Vijayaraghavan K. Treatment of dyslipidemia in patients with type 2 diabetes. Lipids Health Dis. 2010;9(1):1–12. https://doi.org/10.1186/1476-511X-9-144 DOI: https://doi.org/10.1186/1476-511X-9-144

de Macedo GMC, Nunes S, Barreto T. Skin disorders in diabetes mellitus: an epidemiology and physiopathology review. Diabetol Metabo Syndr. 2016;8(1):1–8. https://doi.org/10.1186/s13098-016-0176-y DOI: https://doi.org/10.1186/s13098-016-0176-y

Mooradian AD. Dyslipidemia in type 2 diabetes mellitus. Nat Revi Endocrinol 2009;5(3):150–159. https://doi.org/10.1038/ncpendmet1066 DOI: https://doi.org/10.1038/ncpendmet1066

Garg A, Simha V. Update on dyslipidemia. J Clin Endocrinol Metabol. 2007;92(5):1581–1589. https://doi.org/10.1210/jc.2007-0275 DOI: https://doi.org/10.1210/jc.2007-0275

Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. 2006;444:840–846. https://doi.org/10.1038/nature05482 DOI: https://doi.org/10.1038/nature05482

Katsiki N, Banach M, Mikhailidis D. Is type 2 diabetes mellitus a coronary heart disease equivalent or not? Do not just enjoy the debate and forget the patient! Archiv Med Sci. 2019;15(6):1357–1364. https://doi.org/10.5114/aoms.2019.89449 DOI: https://doi.org/10.5114/aoms.2019.89449

Khan HU, Khan I, Khan AA, Rahman AU, Khan Z, Khan RU. Lipid Profile In type 2 Diabetics versus non-diabetic controls in adult population of district bannu, PAKISTAN. Gomal J Med Sci. 2022;20(1):17–23. https://doi.org/1046903/gjms/20.01.1015 DOI: https://doi.org/10.46903/gjms/20.01.1015

Rehman HU. Co-Relation Between Glycated Hemoglobin (HbA1c) and Dyslipidemia in Type II Diabetics Presenting in a Tertiary Care Hospital in Pakistan. J Pak Soc Intern Med. 2021;2(3):236–240.

Borle AL, Chhari N, Gupta G, Bathma V. Study of prevalence and pattern of dyslipidaemia in type 2 diabetes mellitus patients attending rural health training centre of medical college in Bhopal, Madhya Pradesh, India. Int J Commun Med Public Health. 2016;3(1):832–836. http://dx.doi.org/10.18203/2394-6040.ijcmph20151549 DOI: https://doi.org/10.18203/2394-6040.ijcmph20151549

Dallinga-Thie GM, van Tol A, Hattori H, Van Vark-van der Zee LC, Jansen H, Sijbrands EJG. Plasma apolipoprotein A5 and triglycerides in type 2 diabetes. Diabetologia. 2006;49(7):1505–1511. https://doi.org/10.1007/s00125-006-0261-0 DOI: https://doi.org/10.1007/s00125-006-0261-0

Barter P, Gotto AM, LaRosa JC, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. New England J Med. 2007;357(13):1301–1310. https://doi.org/10.1056/NEJMoa064278 DOI: https://doi.org/10.1056/NEJMoa064278

Rached FH, Chapman MJ, Kontush A. HDL particle subpopulations: Focus on biological function. Biofactors. 2015;41(2):67–77. https://doi.org/10.1002/biof.1202 DOI: https://doi.org/10.1002/biof.1202

Artha IMJR, Bhargah A, Dharmawan NK, et al. High level of individual lipid profile and lipid ratio as a predictive marker of poor glycemic control in type-2 diabetes mellitus. Vasc Health Risk Manag. 2019;15:149–157. https://doi.org/10.2147/VHRM.S209830 DOI: https://doi.org/10.2147/VHRM.S209830

Shahwan MJ, Jairoun AA, Farajallah A, Shanabli S. Prevalence of dyslipidemia and factors affecting lipid profile in patients with type 2 diabetes. Diabetes & Metabolic Syndrome: Clin Res Rev. 2019;13(4):2387–2392. https://doi.org/10.1016/j.dsx.2019.06.009 DOI: https://doi.org/10.1016/j.dsx.2019.06.009

Rahmoun MN, Ghembaza CE, Ghembaza ME-A. Lipid profile in type 2 patients with diabetes from Tlemcen: A Western Algerian population. Diabetes & Metabolic Syndrome: Clin Res Rev. 2019;13(2):1347–1351. https://doi.org/10.1016/j.dsx.2019.02.008 DOI: https://doi.org/10.1016/j.dsx.2019.02.008

Fanni G, Rosato R, Gentile L, et al. Is HDL cholesterol protective in patients with type 2 diabetes? A retrospective population-based cohort study. J Transl Med. 2020;18(1):1–9. https://doi.org/10.1186/s12967-020-02357-1 DOI: https://doi.org/10.1186/s12967-020-02357-1

Biadgo B, Abebe SM, Baynes HW, Yesuf M, Alemu A, Abebe M. Correlation between serum lipid profile with anthropometric and clinical variables in patients with type 2 diabetes mellitus. Ethiop J Health Sci. 2017;27(3):215–226. https://doi.org/10.4314/ejhs.v27i3.3 DOI: https://doi.org/10.4314/ejhs.v27i3.3

Chehade JM, Gladysz M, Mooradian AD. Dyslipidemia in type 2 diabetes: prevalence, pathophysiology, and management. Drugs. 2013;73(4):327–339. https://doi.org/10.1007/s40265-013-0023-5 DOI: https://doi.org/10.1007/s40265-013-0023-5

Published
2024-05-16
How to Cite
Afzal , A., Kausar, R., Aslam, S., Shahid, N., Aman, S., Zohaib, M., Rehman, A., Afzal, N., Abbasi, M. H., Sheikh, N., & Khawar, M. B. (2024). Clinical Biomarkers of Dyslipidemia in Diabetes Mellitus Type II Patients. BioScientific Review, 6(2), 8-19. https://doi.org/10.32350/bsr.62.1
Section
Short Coummunication